LUNG - NASDAQ
Pulmonx Corporation
$1.62
+2.9%Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
At a Glance
Live Snapshotlung
Additional Paid-In Capital
Last Annual Value
573.27M
3-Year CAGR
4%
5-Year CAGR
4%
10-Year CAGR
39%
Pulmonx Corporation Competitors Analysis of Additional Paid-In Capital
| Company | Additional Paid-In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Pulmonx Corporation NASDAQ:LUNG | 573.27M | 2.9% | 3.5% | N/A | |
 Immunic, Inc. NASDAQ:IMUX | 599.24M | 11.2% | 13.1% | 7.1% | |
 TScan Therapeutics, Inc. NASDAQ:TCRX | 627.98M | 16.4% | 19.9% | N/A | |
 Spectral AI, Inc. NASDAQ:MDAI | 50.03M | 17.2% | 17.2% | N/A | |
 NRx Pharmaceuticals, Inc. NASDAQ:NRXP | 290.93M | 6.4% | 7.4% | N/A | |
 Cytosorbents Corporation NASDAQ:CTSO | 310.81M | 0.6% | 1.9% | 8.0% | |
 CEL-SCI Corporation AMEX:CVM | 526.24M | 1.7% | 2.1% | 6.3% | |
 Acrivon Therapeutics, Inc. Common Stock NASDAQ:ACRV | 387.25M | 17.7% | 225.9% | N/A | |
 Assertio Holdings, Inc. NASDAQ:ASRT | 797.45M | 0.3% | 8.4% | 26.5% | |
 Hyperfine, Inc. NASDAQ:HYPR | 371.01M | 3.1% | 2.8% | N/A | |
 PMV Pharmaceuticals, Inc. NASDAQ:PMVP | 551.08M | 1.0% | 3.0% | N/A |
Pulmonx Corporation Fair Value Envelope
Related Guides
Continue your LUNG research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.